Latest News

Date Title Topic
18 Jan 2017 Press Release: Biosimilars Create Opportunities for Sustainable Cancer Care Anticancer agents & Biologic therapy
Pre-IMPAKT 2017 Training Course
16 Jan 2017 ESMO supports the 7th EACR-OECI Joint Training Course: Molecular Pathology Approach to Cancer (8 - 10 May 2017, Amsterdam, Netherlands)
13 Jan 2017 Tailored Scientific Advice to Support Step-by-Step Development of New Biosimilars Bioethics, legal and economic issues
12 Jan 2017 NICE Issues Recommendations for Pembrolizumab in PD-L1-positive Locally Advanced or Metastatic NSCLC After Chemotherapy Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
10 Jan 2017 EU-funded MoTriColor Project for Patients with Metastatic CRC Translational research - Gastrointestinal cancers
09 Jan 2017 NICE Recommends Pertuzumab for the Neoadjuvant Treatment of HER2-positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
23 Dec 2016 EMA Adopts a New Indication for 5-Aminolevulinic Acid Melanoma and other skin tumours - Anticancer agents & Biologic therapy
21 Dec 2016 EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Chlormethine Haematologic malignancies - Anticancer agents & Biologic therapy
21 Dec 2016 ESMO Asia 2016 Media Alert: ESMO Holds Second Successful Congress in Singapore
21 Dec 2016 FDA Grants Accelerated Approval to Rucaparib for Previously Treated, BRCA Mutated Advanced Ovarian Cancer Personalised medicine - Gynaecologic malignancies - Anticancer agents & Biologic therapy
20 Dec 2016 EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab Haematologic malignancies - Anticancer agents & Biologic therapy
19 Dec 2016 ESMO Patient Guides in Liver and Bladder Cancers
19 Dec 2016 EMA Recommends to Extend Indications for Pembrolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
Certificate of Attendance